At its February 2026 meeting, EMA’s human medicines committee (CHMP) recommended 12 medicines for approval, covering vaccines, innovative treatments and biosimilars, and issued two negative opinions.
A major highlight was mCombriax, the first combined mRNA vaccine to protect adults aged 50 and over against both COVID-19 and seasonal influenza. With hundreds of millions of COVID-19 cases reported in Europe and tens of millions of flu cases annually in the EEA, the dual vaccine aims to reduce the burden of seasonal respiratory infections.
“The CHMP’s positive opinion represents an important milestone for respiratory virus vaccination and for Moderna, with the introduction of the world’s first flu plus COVID combination vaccine,” said Stéphane Bancel, Chief Executive Officer of Moderna. “
